The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

DOD prostate cancer research program FY25 funding opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer

Androgen receptor alterations consistently emerged in serial liquid biopsies researchers used to track how metastatic prostate cancer evolves under treatment pressure. These alterations were linked to poorer outcomes across therapies, according to a multi-center collaboration of investigators from Sylvester, UC San Diego, Moores Cancer Center, the University of California, San Francisco, Scripps Research Institute, and Guardant Health. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account